Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.